A metabolomics study of Qiliqiangxin in a rat model of heart failure: a reverse pharmacology approach.
Junzeng FuLiping ChangAmy C HarmsZhenhua JiaHongtao WangCong WeiLi QiaoShuyan TianThomas HankemeierYiling WuMei WangPublished in: Scientific reports (2018)
The Chinese medicine Qiliqiangxin (QL) has been shown to have a protective role in heart failure. Here, we explore the underlying working mechanism of the key therapeutic component in QL using a rat model of heart failure. Heart failure after myocardial infarction was induced surgically and confirmed using echocardiography; a separate group of rats underwent sham surgery. The rats with heart failure were randomly assigned to receive QL, the angiotensin-converting enzyme inhibitor benazepril, or placebo groups. Blood samples were collected from the rats at four time points for up to 8 weeks and used for biochemical analysis and mass spectrometry‒based metabolomics profiling. In total, we measured nine well-known biochemical parameters of heart failure and 147 metabolites. In the rats with heart failure, QL significantly improved these biochemical parameters and metabolomics profiles, significantly increasing the cardioprotective parameter angiopoietin-like 4 and significantly lowering inflammation-related oxylipins and lysophosphatidic acids compared to benazepril. Mechanistically, QL may improve outcome in heart failure by controlling inflammatory process and cardiac hypertrophy. Clinical studies should be designed in order to investigate these putative mechanisms in patients.
Keyphrases
- heart failure
- mass spectrometry
- left ventricular
- cardiac resynchronization therapy
- acute heart failure
- atrial fibrillation
- oxidative stress
- high resolution
- randomized controlled trial
- minimally invasive
- angiotensin converting enzyme
- pulmonary hypertension
- ejection fraction
- coronary artery disease
- clinical trial
- open label
- acute coronary syndrome
- single cell
- drug induced
- gas chromatography
- double blind